Literature DB >> 15187160

Activation of phosphoinositide 3-kinases by the CCR4 ligand macrophage-derived chemokine is a dispensable signal for T lymphocyte chemotaxis.

Darran G Cronshaw1, Charles Owen, Zarin Brown, Stephen G Ward.   

Abstract

Macrophage-derived chemokine (MDC/CC chemokine ligand 22 (CCL22)) mediates its cellular effects principally by binding to its receptor CCR4, and together they constitute a multifunctional chemokine/receptor system with homeostatic and inflammatory roles in the body. We report the CCL22-induced accumulation of phosphatidylinositol-(3,4,5)-trisphosphate (PI(3,4,5)P(3)) in the leukemic T cell line CEM. CCL22 also had the ability to chemoattract human Th2 cells and CEM cells in a pertussis toxin-sensitive manner. Although the PI(3,4,5)P(3) accumulation along with the pertussis toxin-susceptible phosphorylation of protein kinase B were sensitive to the two phosphoinositide 3-kinase inhibitors, LY294002 and wortmannin, cell migration was unaffected. However, cell migration was abrogated with the Rho-dependent kinase inhibitor, Y-27632. These data demonstrate that although there is PI(3,4,5)P(3) accumulation downstream of CCR4, phosphoinositide 3-kinase activity is a dispensable signal for CCR4-stimulated chemotaxis of Th2 cells and the CEM T cell line.

Entities:  

Mesh:

Substances:

Year:  2004        PMID: 15187160     DOI: 10.4049/jimmunol.172.12.7761

Source DB:  PubMed          Journal:  J Immunol        ISSN: 0022-1767            Impact factor:   5.422


  19 in total

1.  CCL17-expressing dendritic cells drive atherosclerosis by restraining regulatory T cell homeostasis in mice.

Authors:  Christian Weber; Svenja Meiler; Yvonne Döring; Miriam Koch; Maik Drechsler; Remco T A Megens; Zuzanna Rowinska; Kiril Bidzhekov; Caroline Fecher; Eliana Ribechini; Marc A M J van Zandvoort; Christoph J Binder; Ivett Jelinek; Mihail Hristov; Louis Boon; Steffen Jung; Thomas Korn; Manfred B Lutz; Irmgard Förster; Martin Zenke; Thomas Hieronymus; Tobias Junt; Alma Zernecke
Journal:  J Clin Invest       Date:  2011-07       Impact factor: 14.808

2.  ROCK insufficiency attenuates ozone-induced airway hyperresponsiveness in mice.

Authors:  David I Kasahara; Joel A Mathews; Chan Y Park; Youngji Cho; Gabrielle Hunt; Allison P Wurmbrand; James K Liao; Stephanie A Shore
Journal:  Am J Physiol Lung Cell Mol Physiol       Date:  2015-08-14       Impact factor: 5.464

Review 3.  The attraction of chemokines as a target for specific anti-inflammatory therapy.

Authors:  James E Pease; Timothy J Williams
Journal:  Br J Pharmacol       Date:  2006-01       Impact factor: 8.739

Review 4.  Phosphoinositide 3-kinase signalling in lung disease: leucocytes and beyond.

Authors:  David A Medina-Tato; Stephen G Ward; Malcolm L Watson
Journal:  Immunology       Date:  2007-08       Impact factor: 7.397

5.  Negative regulation of CXCR4-mediated chemotaxis by the lipid phosphatase activity of tumor suppressor PTEN.

Authors:  Ping Gao; Ronald L Wange; Ning Zhang; Joost J Oppenheim; O M Zack Howard
Journal:  Blood       Date:  2005-06-30       Impact factor: 22.113

6.  Eosinophils are recruited in response to chitin exposure and enhance Th2-mediated immune pathology in Aspergillus fumigatus infection.

Authors:  Evan M O'Dea; Nansalmaa Amarsaikhan; Hongtao Li; Joshua Downey; Emery Steele; Steven J Van Dyken; Richard M Locksley; Steven P Templeton
Journal:  Infect Immun       Date:  2014-05-19       Impact factor: 3.441

7.  Inhibitors of DAG metabolism suppress CCR2 signalling in human monocytes.

Authors:  Priscilla Day; Lisa Burrows; David Richards; Samuel J Fountain
Journal:  Br J Pharmacol       Date:  2019-06-17       Impact factor: 8.739

8.  Ccl22/MDC, is a prostaglandin dependent pyrogen, acting in the anterior hypothalamus to induce hyperthermia via activation of brown adipose tissue.

Authors:  Olivia Osborn; Manuel Sanchez-Alavez; Jeffrey S Dubins; Alejandro Sanchez Gonzalez; Brad Morrison; John R Hadcock; Tamas Bartfai
Journal:  Cytokine       Date:  2010-12-21       Impact factor: 3.861

Review 9.  Clinical utilization of chemokines to combat cancer: the double-edged sword.

Authors:  Chiara Dell'Agnola; Arya Biragyn
Journal:  Expert Rev Vaccines       Date:  2007-04       Impact factor: 5.217

Review 10.  Neoplastic "Black Ops": cancer's subversive tactics in overcoming host defenses.

Authors:  Arya Biragyn; Dan L Longo
Journal:  Semin Cancer Biol       Date:  2012-01-12       Impact factor: 15.707

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.